Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.

ABSTRACT:

Purpose of review

Over the last years, targeted anticancer therapy with small molecule inhibitors and antibodies has much replaced chemoimmunotherapy, which has been the gold standard of care for patients with chronic lymphocytic leukemia (CLL). Here we give an overview of novel targeted agents used in therapy of chronic lymphocytic leukemia, as well as efforts to overcome resistance development, focusing on approved drugs since they gained high relevance in clinical practice.

Recent findings

Novel agents moved to the forefront as a treatment strategy of CLL due to their outstanding efficacy, almost irrespectively of the underlying genetic features. Inhibition of Bruton's tyrosine kinase (BTK), a key molecule in the B cell receptor pathway, achieved dramatic efficacy even in

SUBMITTER: Scheffold A 

PROVIDER: S-EPMC7002327 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature